MedTrace Logo

Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical

NCT01330498 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 229

Last updated 2012-01-06

No results posted yet for this study

Summary

This is an open-label study of patients with relapsing forms of Multiple Sclerosis designed to assess the longitudinal pharmacokinetic, pharmacodynamic, immunological, and biochemical sample collection with MRI and relapse analysis of a Tysabri patient cohort. The study hopes to identify secondary and tertiary risk stratification markers that would aid in the clinical management of patients who are JC antibody positive.

Conditions

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • John F. Foley, MD

    lead OTHER

Principal Investigators

  • John F Foley, MD · Rocky Mountain MS Research Group, LLC

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01330498 on ClinicalTrials.gov